Objective: The number of indications for total hip replacement (THR) and total knee replacement (TKR) surgery is increasing. Enhanced recovery after surgery (ERAS) represents the next step in the evolution of standardised care. The primary aim of this study is to measure the in-hospital 30-day medical and surgical postoperative complications rate. The study's secondary aims are to determine the length of stay, 30-day mortality rate, 30-day reoperation and readmission rates, the ERAS overall compliance and predefined ERAS individual items compliance.
Introduction
Joint replacement surgery for both the hip and knee is one of the most common elective surgical procedures carried out in Europe and in the United States (1) . The number of indications for total hip replacement (THR) and total knee replacement (TKR) surgery is increasing, and a considerable growth in the number of THR and TKR surgical procedures is foreseen during the next decade, which make these surgeries one of the most expensive processes for health services (2) . It is increasingly evident that a sustainable model for joint replacement surgery should emphasise value without compromising patient outcomes. Early functional recovery and hospital stay are important for surgeons, patients and health administrators.
THRs and TKRs are associated with a low risk of morbidity and mortality compared to other surgeries. In general, mortality rates after THRs and TKRs are approximately 0.2%, with morbidity rates of approximately 2.9% (2) . Enhanced recovery after surgery (ERAS) involves the use of multiple perioperative strategies to facilitate the best conditions for surgery and recovery, in an effort to achieve faster hospital discharge and a rapid resumption of normal activities after surgery, through the reduction of perioperative stress. Although individual components may vary, most ERAS programmes include avoiding prolonged fasting, preoperative optimisation of health (recommendations on diet, alcohol consumption, etc.), preoperative carbohydrate loading, patient blood management, goal-directed haemodynamic therapy, multimodal analgesia with opioid avoidance, early withdrawal of tubes (drains, urinary catheter), support of the gastrointestinal function and mobilisation and early feeding (3).
The ERAS protocols have shown repeatedly that they reduce the length of hospital stay (4, 5) without influencing the rates of complications or readmission in abdominal surgery (4, 5) . Despite widespread success in multiple surgical subspecialties, ERAS remains poorly studied and poorly reported in orthopaedic surgery literature. Berend et al. (6) found that adopting a holistic programme of perioperative enhanced recovery reduced inpatient stays and readmissions after THRs and TKRs. However, the authors only reviewed the non-surgical measures and concluded that they can be effective in accelerating recovery. They suggested combining these measures with minimally invasive surgery to achieve the best possible results and a faster recovery (6).
Our objective is to carry out a 60-day state cohort study of patients older than 18 years undergoing elective THRs and TKRs with or without an ERAS programme with any level of compliance with an ERAS protocol (0%-100%) to provide detailed data describing postoperative complications, associated mortality and hospital stay and in addition, to determine if the application of an ERAS programme affects postoperative complications in patients undergoing elective THRs and TKRs and which ERAS individual components have an impact on clinical outcomes.
Methods

Study objectives
The primary aim of POWER.2 is to determine the incidence of predefined medical and surgical postoperative complications at 30 days of follow-up after elective THRs and TKRs in centres with or without an ERAS protocol with any level of protocol compliance (from 0% to 100%). The secondary aims of this study are to determine in-hospital mortality, assess the relationship between ERAS compliance and postoperative complications and assess the influence of each of the predefined ERAS items on postoperative complications.
Study design
We aim to undertake a prospective, multicentre, observational cohort study of consecutive patients undergoing elective THRs and TKRs.
Setting
This study will take place across anesthesiology and orthopaedic surgery units across Spain over a consecutive period of 2 months. Any hospital that offers THRs and/or TKRs will be eligible to participate.
Recruitment
All patients undergoing an elective THRs and TKRs in Spanish participating centres will be eligible for the study. Since adherence to the ERAS protocol will be assessed, no potential hospital will be excluded for having or not having an established ERAS protocol, or for the adherence to ERAS.
Eligibility Criteria
Inclusion criteria
All adult patients (aged >18 years) undergoing an elective THR and TKR surgical procedure will be eligible for this study. Types of approaches for TKRs will include medial parapatellar, midvasto and subvasto (others), with surgical technique of both components cemented, hybrid (not cemented femoral and cemented tibial) or not cemented.
Types of approaches for THRs include posterolateral, anterolateral, lateral direct and direct anterior (other), with surgical technique of both components cemented, hybrid (femoral cemented and acetabular not cemented) or not cemented.
Exclusion criteria
Patient refusal, patients undergoing emergency surgery; patients undergoing partial prostheses, protheses revision or replacement surgeries will be excluded from the study.
Outcome measures
The primary outcome measure is in-hospital 30-day postoperative complications.
Complications are defined and graded according to the standards for definitions and use of outcomes for clinical effectiveness research in perioperative medicine: European Perioperative Clinical Outcome definitions (7), the standardised list and definitions of the Knee Society (8), the Standardised List, Definitions and the Stratification Developed by the Hip Society (9); and the definition and severity of bleeding results from an adaptation from the standardised bleeding definitions for cardiovascular clinical trials (Supplementay Material, Tables 1-3) (10).
Secondary outcome measures will include the length of stay, 30-day mortality rates, 30-day reoperative and readmission rates, the ERAS overall compliance and ERAS individual items compliance. The level of care after surgery will also be recorded as defined in Table 1 . Patient timeline is described in Figure 1 .
Data Collection and Data Management
Each participating local hospital will be responsible for identifying potentially eligible patients for study recruitment. The principal investigator team will consist at least, but not limited to, a consultant orthopaedic surgeon and/or a consultant anaesthetist. Patients will be identified from three clinical areas-outpatient clinic, preoperative assessment clinic and daily elective operating lists-to ensure all potentially eligible patients are captured.
The data collection will be done through an online data collection form via a secure, password-protected platform at each centre with predefined data fields. All data will be anonymised, so patients cannot be tracked, and all anonymised The level of care should be defined according to the care the patient received rather than the location. For example, a patient receiving Level 2 care in a Level 3 area should be recorded as receiving Level 2 care. data will be submitted centrally. A list of patients will be used in each centre to match identification codes in the database of individual patients to record the clinical results and provide any data that may be missing. The required anonymous data fields of this data collection form are shown in Tables 2-5 and include demographic, surgery and anaesthesia related variables, Patient Blood Management variables and ERAS individual item compliance. All anonymised data will be subsequently analysed. Outcome data specific to each surgeon or centre who participates in the study will not be analysed.
Statistical analysis
Sample size calculation
Our plan is to recruit as many centres as possible on a national basis and ask them to include all eligible patients in the study. Only those centres that include at least 10 valid patients will be included in the final data analysis. Those centres that present a smaller number of patients recruited will be evaluated individually, according to their characteristics to be included in the final analysis. We do not have a specific sample size, and the statistical models will be adapted to the event rate provided by the sample recruited.
However, a minimum sample size is estimated, expecting 50% of patients with at least one complication-which are the data that require a larger sample size-with a confidence level of 95% and an accuracy of 3%, of a total of 3012 patients. The larger the sample size, the more accurate it will be. So, it is intended to recruit the largest possible number of centres and patients. We will analyse outcomes depending on whether the patient belonged to an ERAS programme as declared by the hospital where the intervention will be performed. The discrete and continuous variables will be described as n (%) and median (P 25 -P 75 ) and their differences analysed using the Fisher or Pearson and Wilcoxon tests respectively. Subsequently, we 
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will repeat the analysis, subdividing the sample into quartiles according to the real compliance rate of the ERAS items, and comparing the quartiles of higher and lower compliance and calculating a linear fit of the compliance with the variable under study. Next, we will analyse the complications rate for each of the ERAS items using the Fisher test and will perform a multivariate analysis to study the influence in the rate of each of the items together with the clinical and demographic variables. Finally, we will apply the Kaplan-Meier test to determinate whether there were differences in-hospital and critical care length of stay depending on the patient's inclusion in an ERAS programme or the ERAS compliance quartile. To avoid errors by multiple comparisons, we will calculate the respective q-value for each p-value to maintain a false discovery rate below 5%. We will admit as statistically significant those comparisons where the p-value and q-value are below 0.05.
Excel 2010 will be used for data handling, and statistical modelling will be conducted in SPSS V.22.
Methods for minimising bias
All patients will be consecutively screened, and if found to be eligible, informed consent will be obtained. The number of screened, included and analysed patients will be reported, and differences will be explained.
Preoperative data capturing and outcome assessment will be performed by two different investigators. Statistical analysis will be performed after the database closure.
Statistical measurements such as imputation will be taken to minimise the risk of bias due to incomplete outcome data. The results of this study will be prepared in accordance with guidelines set by the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement for observational studies (11).
To avoid the risk of selective reporting, the trial protocol with full information about oucomes and variables is hereby published. Any financial relationship or any conflict of interest that could inappropriately influence the work within this project will be stated explicitly. Confounding will be minimised by inclusion of covariates and factors in the statistical analysis of the primary end point.
Additional analyses and data sharing
We have developed a process for enabling us to consider requests from investigators outside the Steerning Committee to conduct secondary analyses on POWER.2 data. This includes formal consideration by the POWER.2 project team and steering committees using a predefined standard data sharing request form. 
Ethical approval
Project management
The POWER.2 Steering Committee will be responsible for protocol development, data collection and data analysis. A structured system of regional and local leadership has been created to coordinate the POWER.2 study. Regional leads will recruit, advice and ensure the correct approvals are in place for each hospital within their region. Local leads will oversee data collection in their hospital, ensuring adherence to local governance protocols and continuous data collection.
Results
Dissemination
The protocol will be disseminated through the Spanish Perioperative Audit and Research Network (RedGERM), the Spanish Society of Anaesthesia and Critical Care (SEDAR) and the 'Grupo Español de Rehabilitación Multimodal' (GERM). All protocol documents and relevant clinical toolkits will be made available through the POWER.2 website (www.grupogerm.es/power2). Individual unit data will be presented at local meetings. Overall collective data will be published in peer-reviewed journals. It is anticipated that the results from this prospective study will help inform ongoing clinical research and will be used to inform commissioning and implement changes within the Spanish National Health Service.
Discussion
Currently, there is no agreed consensus on the optimal perioperative strategy in patients undergoing elective THRs and TKRs. Due to the large differences in the number and nature of the individual elements included in the ERAS programmes, the incomplete information in the studies, the lack of standardisation in the ERAS programmes and the lack of agreement on what constitutes an ERAS protocol, there is little evidence about which specific protocol elements are those that are associated independently with improvements in the postoperative outcome. Although this occurs in other surgical disciplines, it is especially important in orthopaedic surgery. Overall, a high level of participation is expected at the national level, which is why the data obtained will make it possible to clearly establish the key ERAS elements as well as the patients who will benefit most from the ERAS protocol and, on the other hand, identify those areas in which more research is needed.
Our study is, to the best of our knowledge, novel for investigating current perioperative management in patients undergoing elective THRs and TKRs and its subsequent impact on clinical outcomes with collaborative support from orthopaedic surgeons and anaesthetists. Moreover, we hope to reach a high number of patients included in a very short period of time, which makes the data obtained more reliable. We also will investigate current Patient Blood Management (PBM) programme influences in the ERAS programme. Preoperative anaemia is quite frequent in these patients, and even if mild, it is associated with worse outcomes (12). We will analyse the impact of PBM measures on the improvement of ERAS programme benefits.
Conclusion
The data generated from this prospective, multicentre and observational cohort study will help to identify and plan future research areas, evaluate the efficacy of ERAS protocols in the elective practice of THRs and TKRs, develop a consensus on appropriate clinical endpoints and accumulate data for the generation of power calculations to develop future randomised controlled trials. clinical treatment.
2) The infection appears to be related to the surgical -Severe: Results in significant prolongation of procedure and involves deep soft tissues of the hospital stay and/or permanent functional incision (e.g. fascial and muscle layers).
limitation or death. Almost always requires 3) The patient has at least one of the following:
clinical treatment. a) Purulent drainage from the deep incision but not from the organ/space component of the surgical site b) A deep incision spontaneously dehisces or is deliberately opened by a surgeon and is culture positive or no cultures were taken whilst the patient has at least one of the following signs or symptoms of infection: fever (>38°C) or localised pain or tenderness. A culture-negative finding does not meet this criterion. c) An abscess or other evidence of infection involving the deep incision is found on direct examination, during surgery, or by a histopathologic or radiologic examination d) Diagnosis of a deep incisional surgical site infection by a surgeon or attending physician
Surgical site infection
An infection which involves any part of the body -Mild: Results in only temporary harm and would (organ/space) excluding the fascia or muscle layers and meets the not usually require specific clinical treatment. following criteria:
-Moderate: More serious complication, but one 1) Infection occurs within 30 days after surgery.
which does not usually result in permanent harm 2) The infection appears to be related to the or functional limitation. Usually requires clinical surgical procedure and involves any part of the treatment. body, excluding the skin incision, fascia, or muscle -Severe: Results in significant prolongation of layers, that is opened or manipulated during the hospital stay and/or permanent functional operative procedure. limitation or death. Almost always requires 3) The patient has at least one of the following: clinical treatment. a) Purulent drainage from a drain that is placed through a stab wound into the organ/space b) Organisms isolated from an aseptically obtained culture of fluid or tissue in the organ/ space c) An abscess or other evidence of infection involving the organ/space that is found on direct examination, during reoperation, or by histopathologic or radiologic examination d) Diagnosis of an organ/space surgical site infection by a surgeon or attending physician
Bloodstream infection
An infection which is not related to infection at -Mild: Results in only temporary harm and would another site and which meets either of the not usually require specific clinical treatment. following criteria:
-Moderate: More serious complication but one 1) Patient has a recognised pathogen cultured from which does not usually result in permanent harm blood cultures which is not related to an infection or functional limitation. Usually requires clinical at another site. 
